Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Up 48.3% in September

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 663,800 shares, a growth of 48.3% from the September 15th total of 447,500 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 6,638.0 days. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 6,638.0 days.

Swedish Orphan Biovitrum Price Performance

Shares of Swedish Orphan Biovitrum stock opened at $33.30 on Friday. Swedish Orphan Biovitrum has a 52-week low of $25.80 and a 52-week high of $33.30. The company has a 50 day moving average of $30.80 and a 200 day moving average of $29.94. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $11.85 billion, a P/E ratio of -475.71 and a beta of 0.49.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings results on Monday, October 20th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. Swedish Orphan Biovitrum had a negative net margin of 0.97% and a positive return on equity of 13.61%. The company had revenue of $826.53 million during the quarter, compared to the consensus estimate of $818.86 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.